Results 271 to 280 of about 1,518,423 (359)

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium. [PDF]

Blood Adv
Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R.   +29 more
europepmc   +1 more source

Interchange Fees in Payment Networks – Implications for Prices, Profits, and Welfare

Robert M. Hunt, Konstantinos Serfes, Yin Zhang   +2 more
openalex   +1 more source

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms

British Journal of Clinical Pharmacology, EarlyView.
Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola, Zachary N. Stowe, Marc L. Kalin, Michael D. Evans, Catherine M. Sherwin, Maged M. Costantine, D. Jeffrey Newport, James C. Ritchie, Angela K. Birnbaum   +8 more
wiley   +1 more source

Health facilities readiness and associated factors to provide growth monitoring services in low-income and middle-income countries: evidence from national service provision assessment surveys of six countries. [PDF]

BMJ Open
Assefa DT, Belete NK, Gebretsadik MK.
europepmc   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Differences in spinal structural lesions between patients with early axSpA and non-axSpA chronic back pain: 2-year SPACE cohort results. [PDF]

Rheumatology (Oxford)
Ayan G, de Bruin L, van Lunteren M, de Hooge M, Bento da Silva A, Marques ML, Reijnierse M, Navarro-Compán V, van de Sande M, Berg IJ, Ramonda R, Exarchou S, van der Heijde D, van Gaalen F, Ramiro S.   +14 more
europepmc   +1 more source

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J. Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed   +11 more
wiley   +1 more source